Bio-Techne Balance Sheet Health
Financial Health criteria checks 6/6
Bio-Techne has a total shareholder equity of $2.1B and total debt of $300.0M, which brings its debt-to-equity ratio to 14%. Its total assets and total liabilities are $2.7B and $597.4M respectively. Bio-Techne's EBIT is $243.8M making its interest coverage ratio 25.2. It has cash and short-term investments of $187.5M.
Key information
14.0%
Debt to equity ratio
US$300.00m
Debt
| Interest coverage ratio | 25.2x |
| Cash | US$187.54m |
| Equity | US$2.14b |
| Total liabilities | US$597.37m |
| Total assets | US$2.74b |
Recent financial health updates
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Recent updates
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings
Nov 06Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Financial Position Analysis
Short Term Liabilities: TECH's short term assets ($648.6M) exceed its short term liabilities ($142.1M).
Long Term Liabilities: TECH's short term assets ($648.6M) exceed its long term liabilities ($455.2M).
Debt to Equity History and Analysis
Debt Level: TECH's net debt to equity ratio (5.3%) is considered satisfactory.
Reducing Debt: TECH's debt to equity ratio has reduced from 42.5% to 14% over the past 5 years.
Debt Coverage: TECH's debt is well covered by operating cash flow (101.2%).
Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (25.2x coverage).